Mao-Ying Qi-Liang, Kavelaars Annemieke, Krukowski Karen, Huo Xiao-Jiao, Zhou Wenjun, Price Theodore J, Cleeland Charles, Heijnen Cobi J
Neuroimmunology Laboratory, Department of Symptom Research, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America; Department of Integrative Medicine and Neurobiology, State Key Laboratory of Medical Neurobiology, School of Basic Medical Sciences, Fudan University, Shanghai, People's Republic of China.
Neuroimmunology Laboratory, Department of Symptom Research, University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States of America.
PLoS One. 2014 Jun 23;9(6):e100701. doi: 10.1371/journal.pone.0100701. eCollection 2014.
Chemotherapy-induced peripheral neuropathy (CIPN) characterized by loss of sensory sensitivity and pain in hands and feet is the major dose-limiting toxicity of many chemotherapeutics. At present, there are no FDA-approved treatments for CIPN. The anti-diabetic drug metformin is the most widely used prescription drug in the world and improves glycemic control in diabetes patients. There is some evidence that metformin enhances the efficacy of cancer treatment. The aim of this study was to test the hypothesis that metformin protects against chemotherapy-induced neuropathic pain and sensory deficits. Mice were treated with cisplatin together with metformin or saline. Cisplatin induced increased sensitivity to mechanical stimulation (mechanical allodynia) as measured using the von Frey test. Co-administration of metformin almost completely prevented the cisplatin-induced mechanical allodynia. Co-administration of metformin also prevented paclitaxel-induced mechanical allodynia. The capacity of the mice to detect an adhesive patch on their hind paw was used as a novel indicator of chemotherapy-induced sensory deficits. Co-administration of metformin prevented the cisplatin-induced increase in latency to detect the adhesive patch indicating that metformin prevents sensory deficits as well. Moreover, metformin prevented the reduction in density of intra-epidermal nerve fibers (IENFs) in the paw that develops as a result of cisplatin treatment. We conclude that metformin protects against pain and loss of tactile function in a mouse model of CIPN. The finding that metformin reduces loss of peripheral nerve endings indicates that mechanism underlying the beneficial effects of metformin includes a neuroprotective activity. Because metformin is widely used for treatment of type II diabetes, has a broad safety profile, and is currently being tested as an adjuvant drug in cancer treatment, clinical translation of these findings could be rapidly achieved.
化疗引起的周围神经病变(CIPN)表现为手足感觉敏感性丧失和疼痛,是许多化疗药物的主要剂量限制性毒性。目前,美国食品药品监督管理局(FDA)尚未批准用于治疗CIPN的药物。抗糖尿病药物二甲双胍是世界上使用最广泛的处方药,可改善糖尿病患者的血糖控制。有证据表明二甲双胍可提高癌症治疗的疗效。本研究的目的是验证二甲双胍可预防化疗引起的神经性疼痛和感觉缺陷这一假设。小鼠接受顺铂与二甲双胍或生理盐水联合治疗。使用von Frey试验测量发现,顺铂会导致对机械刺激的敏感性增加(机械性异常性疼痛)。二甲双胍联合给药几乎完全预防了顺铂引起的机械性异常性疼痛。二甲双胍联合给药还预防了紫杉醇引起的机械性异常性疼痛。小鼠检测后爪上粘性贴片的能力被用作化疗引起的感觉缺陷的一种新指标。二甲双胍联合给药预防了顺铂引起的检测粘性贴片潜伏期增加,表明二甲双胍也可预防感觉缺陷。此外,二甲双胍预防了顺铂治疗后爪部表皮内神经纤维(IENF)密度的降低。我们得出结论,在CIPN小鼠模型中,二甲双胍可预防疼痛和触觉功能丧失。二甲双胍可减少外周神经末梢损失这一发现表明,二甲双胍有益作用的潜在机制包括神经保护活性。由于二甲双胍广泛用于治疗II型糖尿病,具有广泛的安全性,且目前正在作为癌症治疗的辅助药物进行试验,因此这些发现有望迅速实现临床转化。